Skip to main content
. Author manuscript; available in PMC: 2016 Feb 23.
Published in final edited form as: Vaccine. 2015 Sep 15;33(42):5553–5563. doi: 10.1016/j.vaccine.2015.09.005

Table 1.

Breadth of cross-neutralization. In vitro neutralizing antibody titers (IVNT) in sera at 0.5 and 3 months post vaccination of mice with Cervarix (0.1× human dose) as a positive control, or wild type AAVLP (wt) or AAVLP (HPV16/31 L2) at either a low dose (0.6 μg) or medium dose (6 μg) in no adjuvant, or alum, alum + MPL or Ribi adjuvant or mixed with Cervarix (*which contains alum + MPL). N.D. < 1:50.

Vaccination groups
 HPV16 IVNT HPV45 IVNT HPV58 IVNT HPV18 IVNT HPV31 IVNT
Antigen Dose Adjuvant 2 wks
3 mths		 2 wks
3 mths		 2 wks
3 mths		 2 wks
3 mths		 2 wks
3 mths
AAVLP (HPV) Low N.D. N.D. N.D. N.D. N.D.
N.D. N.D. N.D. N.D. N.D.
AAVLP (HPV) Medium N.D. N.D. N.D. N.D. N.D.
N.D. N.D. N.D. N.D. N.D.
AAVLP (HPV)+ Cervarix Medium + 0.1× Alum + MPL* 409,600 100 N.D. >12,800 N.D.
102,400 100 N.D. >12,800 N.D.
AAVLP (HPV) Low Alum 100 N.D. 50 N.D. N.D.
100 N.D. 50 N.D. N.D.
AAVLP (HPV) Medium Alum 100 N.D. N.D. N.D. N.D.
100 N.D. N.D. N.D. N.D.
AAVLP (HPV) Low Alum + MPL 100 N.D. N.D. N.D. N.D.
100 N.D. N.D. N.D. N.D.
AAVLP (HPV) Medium Alum + MPL 200 N.D. 50 100 N.D.
200 N.D. 100 50 N.D.
AAVLP (HPV) Low Ribi 400 50 200 400 100
200 50 400 200 200
AAVLP (HPV) Medium Ribi 400 50 200 400 100
200 N.D. 100 100 50
AAVLP (wt) Medium Alum N.D. N.D. N.D. N.D. N.D.
N.D. N.D. N.D. N.D. N.D.
AAVLP (wt) Medium Alum + MPL N.D. N.D. N.D. N.D. N.D.
N.D. N.D. N.D. N.D. N.D.
AAVLP (wt) Medium Ribi N.D. N.D. N.D. N.D. N.D.
N.D. N.D. N.D. N.D. N.D.
Cervarix 0.1× Alum + MPL* 409,600 400 N.D. >12,800 N.D.
204,800 N.D. N.D. >12,800 N.D.